APA (7th ed.) Citation

Häring, H., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., . . . Investigators, E. M. T. (2013). Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care, 36(11), 3396. https://doi.org/10.2337/dc12-2673

Chicago Style (17th ed.) Citation

Häring, Hans-Ulrich, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J. Woerle, Uli C. Broedl, and EMPA-REG METSU Trial Investigators. "Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients with Type 2 Diabetes: A 24-week, Randomized, Double-blind, Placebo-controlled Trial." Diabetes Care 36, no. 11 (2013): 3396. https://doi.org/10.2337/dc12-2673.

MLA (9th ed.) Citation

Häring, Hans-Ulrich, et al. "Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients with Type 2 Diabetes: A 24-week, Randomized, Double-blind, Placebo-controlled Trial." Diabetes Care, vol. 36, no. 11, 2013, p. 3396, https://doi.org/10.2337/dc12-2673.